Anti-IL-6 antibody [EPR20653]
- RabMAb
- Recombinant
- KO Validated
- 20ul selling size
- What is this?
Be the first to review this product! Submit a review
|
(16 Publications)
Rabbit Recombinant Monoclonal IL-6 antibody. Suitable for IP, WB, ICC/IF and reacts with Human samples. Cited in 16 publications.
View Alternative Names
IFNB2, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, CTL differentiation factor, Hybridoma growth factor, Interferon beta-2, BSF-2, CDF, IFN-beta-2
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-IL-6 antibody [EPR20653] (AB214429)
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (human umbilical vein endothelial cell line) cells, untreated or treated with Lipopolysaccharides (LPS) (0.5 μg/ml 24 hours) and Brefeldin A (BFA) (300 ng/ml 20 hours), labeling IL6 with ab214429 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing the cytoplasmic expression increased on HUVEC cells treated with Lipopolysaccharides (LPS) (0.5 μg/ml, 24 hours) and Brefeldin A (BFA) (300 ng/ml, 20 hours).
The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.
Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
- IP
Supplier Data
Immunoprecipitation - Anti-IL-6 antibody [EPR20653] (AB214429)
IL6 was immunoprecipitated from 0.35 mg of HUVEC (human umbilical vein endothelial cell line) treated with Lipopolysaccharides (LPS) and Brefeldin A (BFA) whole cell lysate with ab214429 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab214429 at 1/1,000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10,000 dilution
Lane 1 : HUVEC treated with 0.5 μg/ml LPS for 24 hours and 300 ng/ml BFA for 20 hours whole cell lysate 10 μg (Input).
Lane 2 : ab214429 IP in HUVEC treated with 0.5 μg/ml LPS for 24 hours and 300 ng/ml BFA for 20 hours whole cell lysate (+).
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab214429 in HUVEC treated with 0.5 μg/ml LPS for 24 hours and 300 ng/ml BFA for 20 hours whole cell lysate (-).
Blocking/Dilution buffer : 5% NFDM/TBST.
Exposure time : 3 minutes.
All lanes:
Immunoprecipitation - Anti-IL-6 antibody [EPR20653] (ab214429)
Predicted band size: 23 kDa
Observed band size: 21-28 kDa
false
- WB
Supplier Data
Western blot - Anti-IL-6 antibody [EPR20653] (AB214429)
Blocking/Dilution buffer : 5% NFDM/TBST.
The MW observed is consistent with the literature (PMID : 2523818, PMID : 2783321).
All lanes:
Western blot - Anti-IL-6 antibody [EPR20653] (ab214429) at 1/1000 dilution
Lane 1:
Untreated HUVEC (human umbilical vein endothelial cell line) whole cell lysate at 10 µg
Lane 2:
HUVEC treated with 0.5 μg/ml Lipopolysaccharides (LPS) for 24 hours and 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 23 kDa
Observed band size: 21-28 kDa
true
Exposure time: 30s
- WB
Lab
Western blot - Anti-IL-6 antibody [EPR20653] (AB214429)
Lanes 1 - 4 : Merged signal (red and green). Green - ab214429 observed at 25 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
ab214429 was shown to react with IL-6 in wild-type A549 cells in western blot with loss of signal observed in IL-6 knockout cell line ab273751 (knockout cell lysate ab275501). Wild-type and IL-6 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab214429 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 1000 Dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-IL-6 antibody [EPR20653] (ab214429) at 1/1000 dilution
Lane 1:
Wild-type A549 Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5ug/ml, 4h) cell lysate at 30 µg
Lane 2:
Wild-type A549 IL-1β (<a href='/en-us/products/proteins-peptides/recombinant-human-il-1-beta-protein-active-ab259387'>ab259387</a>) (20 ng/ml, 24h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5 ug/ml for the last 4h) cell lysate at 30 µg
Lane 2:
Western blot - Human IL-6 knockout A549 cell line (<a href='/en-us/products/cell-lines/human-il-6-knockout-a549-cell-line-ab273751'>ab273751</a>)
Lane 3:
IL-6 knockout A549 Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5ug/ml, 4h) cell lysate at 30 µg
Lane 4:
IL-6 knockout A549 IL-1β (<a href='/en-us/products/proteins-peptides/recombinant-human-il-1-beta-protein-active-ab259387'>ab259387</a>) (20 ng/ml, 24h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5 ug/ml for the last 4h) cell lysate at 30 µg
Predicted band size: 23 kDa
Observed band size: 25 kDa,35 kDa
false
- WB
Lab
Western blot - Anti-IL-6 antibody [EPR20653] (AB214429)
Lanes 1 - 4 : Merged signal (red and green). Green - ab214429 observed at 25 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
ab214429 was shown to react with IL-6 in wild-type A549 cells in western blot with loss of signal observed in IL-6 knockout cell line ab273751 (knockout cell lysate ab275501). Wild-type A549 and IL-6 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab214429 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 1000 Dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-IL-6 antibody [EPR20653] (ab214429) at 1/1000 dilution
Lane 1:
Wild-type A549 Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5ug/ml, 4h) cell lysate at 30 µg
Lane 2:
Wild-type A549 IL-1β (<a href='/en-us/products/proteins-peptides/recombinant-human-il-1-beta-protein-active-ab259387'>ab259387</a>) (20 ng/ml, 24h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5 ug/ml for the last 4h) cell lysate at 30 µg
Lane 3:
IL-6 knockout A549 Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5ug/ml, 4h) cell lysate at 30 µg
Lane 4:
IL-6 knockout A549 IL-1β (<a href='/en-us/products/proteins-peptides/recombinant-human-il-1-beta-protein-active-ab259387'>ab259387</a>) (20 ng/ml, 24h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5 ug/ml for the last 4h) cell lysate at 30 µg
false
Related conjugates and formulations (1)
-
Anti-IL-6 antibody [EPR20653] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IL-6 influences immune regulation and acts as part of the acute phase response. It stimulates the production of acute-phase proteins and supports the differentiation of B cells into antibody-producing cells. IL-6 is not known to be part of a larger complex acting primarily as a single entity in signal transduction. Moreover IL-6 impacts the metabolism of iron and bone homeostasis showing its multifunctional nature.
Pathways
IL-6 forms an integral part of several signaling routes particularly the JAK-STAT pathway. In this context IL-6 interacts with signal transducer proteins like STAT3 to transmit signals from the cell surface to the nucleus affecting gene expression. Another important pathway is the MAPK pathway through which IL-6 influences cell proliferation and survival. These interactions reflect IL-6's diverse effects in cellular processes.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (16)
Recent publications for all applications. Explore the full list and refine your search
Degenerative neurological and neuromuscular disease 15:81-94 PubMed40937143
2025
Applications
Unspecified application
Species
Unspecified reactive species
ACS omega 10:36994-37003 PubMed40893218
2025
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 15:24797 PubMed40634479
2025
Applications
Unspecified application
Species
Unspecified reactive species
Stem cell research & therapy 16:253 PubMed40394699
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of materials science. Materials in medicine 35:72 PubMed39614937
2024
Applications
Unspecified application
Species
Unspecified reactive species
Biotechnology and applied biochemistry 72:355-368 PubMed39279255
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cancer cell international 23:219 PubMed37759302
2023
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 26:526 PubMed37869633
2023
Applications
Unspecified application
Species
Unspecified reactive species
Gut microbes 15:2197836 PubMed37017266
2023
Applications
Unspecified application
Species
Unspecified reactive species
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 37:e22834 PubMed36961378
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com